

# Fusion of short telomeres in human cells is characterized by extensive deletion and microhomology, and can result in complex rearrangements

Boitelo T. Letsolo, Jan Rowson and Duncan M. Baird\*

Department of Pathology, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK

Received September 8, 2009; Revised November 18, 2009; Accepted December 3, 2009

## ABSTRACT

**Telomere fusion is an important mutational event that has the potential to lead to large-scale genomic rearrangements of the types frequently observed in cancer. We have developed single-molecule approaches to detect, isolate and characterize the DNA sequence of telomere fusion events in human cells. Using these assays, we have detected complex fusion events that include fusion with interstitial loci adjacent to fragile sites, intra-molecular rearrangements, and fusion events involving the telomeres of both arms of the same chromosome consistent with ring chromosome formation. All fusion events were characterized by the deletion of at least one of the telomeres extending into the sub-telomeric DNA up to 5.6 kb; close to the limit of our assays. The deletion profile indicates that deletion may extend further into the chromosome. Short patches of DNA sequence homology with a G:C bias were observed at the fusion point in 60% of events. The distinct profile that accompanies telomere fusion may be a characteristic of the end-joining processes involved in the fusion event.**

## INTRODUCTION

By capping the ends of linear chromosomes and preventing fusion, telomeres play a key role in upholding chromosomal integrity. The loss of the end-capping function can occur as a consequence of gradual telomere erosion or stochastic telomeric deletion; both of which can create short dysfunctional telomeres (1–3). The end-capping function can also be abrogated by the experimental disruption of the telomeric protein structure, which creates

telomeres that are dysfunctional, but full length (4). The loss of telomere function can result in the fusion of telomeres with other telomeric loci, or non-telomeric double-stranded DNA breaks; this can result in the formation of dicentric chromosomes. With ongoing cell division the resulting cycles of anaphase-bridging, breakage and fusion can result in genomic rearrangements such as non-reciprocal translocations (NRTs) and localized amplifications that are common in a broad spectrum of tumour types (5–8). It is thus considered that telomere dysfunction may facilitate progression in the early stages of tumourigenesis. Consistent with this, telomere length is reduced in some types of carcinoma compared to matched normal tissue (9–11) and an increase in anaphase-bridging, a surrogate marker of telomere fusion, is detected at the adenoma-carcinoma transition, a point that is characterized by increased chromosomal instability in colorectal carcinoma (12), breast (13) and oral squamous cell carcinomas (14). Furthermore, breakpoint frequency and telomere length is negatively correlated at specific chromosome ends in some carcinoma derived cells (15–17). These data are backed up by evidence from telomerase knockout mouse models, which show that telomere loss correlates with genomic instability which may drive a higher rate of tumour formation and a lower age of onset (18,19). Carcinomas from telomerase knockout mice contain high frequencies of chromosomes lacking telomeric signals, anaphase bridges, NRTs and end-to-end fusions (6).

If the telomere repeat array and the subtelomeric sequences remain intact, telomere fusion between sister chromatids will generate inverted repeats that may create fragile sites, such that a subsequent breakage may then occur close to the site of the original telomere fusion (20): a second round sister chromatid fusion of the broken chromosome, may then result in further amplification. Thus, in addition to large-scale genomic rearrangements,

\*To whom correspondence should be addressed. Tel: +44 0 29 2068 7038; Fax: +44 0 29 2068 7343; Email: bairddm@cardiff.ac.uk

such as NRTs, sister chromatid telomere fusion and cycles of anaphase-bridging, breakage and fusion can result in localized gene amplification (21). Hence, short dysfunctional telomeres have the potential to create the types of mutation that may drive progression in the early stages of cancer, it is therefore of interest to understand the mechanistic basis of telomere fusion in human cells.

Experimental intervention in the protein structure of the telomere, such as abrogating the function of TRF2, results in immediate telomeric de-protection and fusion that is dependent upon factors required for non-homologous end-joining (NHEJ), including ligase IV, DNA PKcs and Ku (22,23). However in contrast, the fusion of short dysfunctional telomeres in telomerase mutants of Yeast, *Arabidopsis* and mice is independent of Ku70, DNA-PKcs and Ligase IV (1,24–26). These data imply that critically shortened telomeres may be subjected to fusion that is mediated by alternative end-joining mechanisms. We have investigated fusion between short dysfunctional telomeres in human cells using a PCR-based assay that detects single-molecule telomere fusion events. This revealed that fusion was accompanied by deletion and short patches of homology at the fusion point (2). We have now expanded this assay, which was previously based on just two chromosome ends, to include at least 43% of telomeres in the human genome. Sequence analysis of a large set of telomere fusion events revealed more extensive sub-telomeric deletions that extend up to the limit of our assays (6.1 kb) that are consistent with error-prone DNA-PK independent end-joining (27–30). In addition, fusion events were characterized by short patches of homology at the fusion point that exhibited a G:C bias. We also observed events that may result in large-scale genomic rearrangements, including, fusion events that are consistent with chromosome circularization, fusion with interstitial telomeres, and intra-molecular fusion prior to chromosomal fusion.

## MATERIALS AND METHODS

### Cell culture

Telomerase expressing HEK293 cells that were originally derived from human embryonic kidney cells transformed with adenoviral DNA (31), were cultured in 88% Dulbecco's Modified Eagle's Medium (DMEM; containing 4500 mg/l D-glucose, 110 mg/l sodium pyruvate, and non-essential amino acids but no L-glutamine), supplemented with 10% (v/v) Foetal Calf Serum,  $1 \times 10^5$  IU/l penicillin, 100 mg/l streptomycin and 2 mM glutamine. Telomerase negative MRC5 clonal fibroblasts expressing human papillomavirus oncoproteins E6 E7 used in this study have been described previously (2). We defined the onset of replicative senescence (M1) as at least 2 weeks of no cell growth and BrdU labelling indices of <1%. M2 'crisis' was defined as when the cell culture ceases to expand following replicative span extension beyond senescence (32).

### DNA extraction

Genomic DNA was extracted by standard proteinase K, RNase A and phenol/chloroform protocols (33). High molecular weight DNA was solubilized by either digesting with EcoRI or serial dilutions in 10 mM Tris-HCl (pH 8.0) to ~100 ng/μl, prior to quantifying the DNA in triplicate by Hoechst 33258 fluorometry.

### Telomere fusion assay


Several primers were designed within the sub-telomeric repeat regions that are shared among multiple chromosomes. Primers that target some of the TelBamII and TelBam 3.4 classes of subtelomeric repeat regions (34–36) were designed using the 21q and 16p telomere-adjacent sequences respectively (35).

The telomere fusion assay was then carried out as described previously (2) with the following modifications. The EcoRI solubilized DNA was used in the assay with the 21q group primers and 100 ng/μl Tris diluted DNA for the 16p group primers. PCR reactions to detect fusion involving the 21q group telomeres were undertaken with XpYpM/17p6 and 21q1 and for the 16p group with XpYpM/17p6 and 16p1 primers. Fusion molecules were detected and the frequencies quantified by Southern blotting and hybridization with the XpYp and 17p telomere-adjacent probes as described previously (2). In order to determine the chromosomes participating in the fusion events for subsequent sequence characterization, further hybridizations were undertaken with the 21q or 16p telomere-adjacent probes generated by PCR with 21qseq1/21qseq1rev or the 16p2/16pseq1rev PCR primers (Figure 1A), these probes yield additional non-specific products and thus were not used for quantification. Any fusion products were then re-amplified for direct sequence analysis using nested PCR primers (XpYpO, 17p7, 21qseq1 and 16p2, Figure 1A) as determined by Southern hybridization, as described previously (2).

To provide an estimate of the frequency of fusion, the total number of bands generated from each DNA analysed was counted and the number of input molecules in each analysis was estimated from the amount of DNA used in each reaction together with the size of a diploid human genome. Thus, the frequency of fusion could be calculated from the number of positive molecules compared to the number of input molecules. This will represent an underestimate of the total telomere fusion frequency as the fusion assays described here are capable of detecting a small fraction of the total number of different pair wise telomere fusion combinations in the human genome.

### Oligonucleotides

XpYp and 17p primers used during this study have been described previously (2). The chromosome ends that previously hybridized to the TelBam11 probe (21q, 1q, 2q, 5q, 6q, 8p, 8q, 10q, 13q, 17q, 19p, 19q, 22q and the 2q13 interstitial telomeric locus) and to the TelBam3.4 probe (16p, 1p, 9p, 12p, 15q, XqYq ant the 2q14



**Figure 1.** Illustrating the single molecule telomere fusion assay. (A) Diagrammatic representation of oligonucleotide primers used for the PCR reaction; the XpYp and 17p primers are specific to those chromosome end; the 21q group primers are capable of amplifying the telomeres of 1q, 2q, 5q, 6q, 6p, 8p, 10q, 13q, 19p, 19q, 22q and 2q13; the 16p group amplifies the telomeres of 1p, 9p, 12p, 15q 16p and XqYq as well as the 2q14. (B) Examples of telomere fusion gels, showing the improvement in the sensitivity of the PCR reaction when the additional telomeres are included in the reaction, as indicated on the left. HEK293, and MRC5 E6E7 with population doublings (PD), are indicated above. Each reaction contains 100 ng of DNA, and the fusion products were detected with the XpYp telomere adjacent probe. The frequency at which fusion was detected is indicated below each analysis, molecular weight markers are indicated on the right.

interstitial locus) probes (34,36) were termed 21q and 16p groups, respectively (Figure 1A). The primers for the telomere fusion assay were designed for both groups within the sub-telomeric regions of the 21q and 16p sequences (35,36) (Table 1).

## RESULTS

### Telomere fusion assay

We have previously developed a single-molecule PCR-based telomere fusion assay for two chromosome ends, XpYp and 17p. The sub-telomeric sequence of



**Table 1.** Oligonucleotide sequences for fusion analysis

Fusion PCR	
21q1:	5'-CTTGGTGTGCGAGAGAGGTAG-3'
16p1:	5'-TGGACTTCTCACTTCTAGGGCAG-3'
Sequencing	
16pseq1:	5'-TGCCTCACCTCTCTGGGCCAG-3'
XqYqseq2:	5'-GTTGCTCTGACATGGACACAG-3'
16pseq4:	5'-TGGGTCTGGCAACACTCTG-3'
16p2seqB:	5'-GCTCCAGATGACATCACAGGG-3'
16p6:	5'-CTCCACTCCAGTGCTCAGCTTG-3'
16p2:	5'- TCACTGCTGTATCTCCAGTG -3'
1pseq2BT:	5'-TGCAGCTGCCTGTCTCAGGAAG-3'
1pseqA:	5'-TCAGTGACAGACACGGGTCTC-3'
16pseq1rev:	5'-GCTGGGTGAGCTTAGAGAGGAAAGC-3'
16pseq3:	5'-TCCAGGGCTTACCTGCTAG-3'
16p5:	5'-TAGCATGTGTCTCTGCGCCTG-3'
21q2CT:	5'-TGCAATGTCCCTAGCTGCCAG-3'
21qseq1:	5'-TGGTCTTATACTGTGTTC -3'
21q3:	5'-CTGCAGTTGTCCTAGTCGC-3'
10q1:	5'-AGGTTCCACTCGTCTCTGCG-3'
10q2:	5'-TGCAATGTCCCTAGCTGCCAG-3'
8p1:	5'-TGCACAGGACTCTTAGGCTG-3'
Subtel2:	5'-GAATCCTGCGACCGAGATTCTC-3'
21qseq2:	5'-TGCCCCAATCATCATTCACTGC-3'
21qseq1rev:	5'-AGCTAGTACTACTTAAACAGAGC-3'
6p1:	5'-CTGCACAGGACTCCTAGGATG-3'


these telomeres is sufficiently unique such that sequence-specific telomere length and fusion assays have been developed (2,37–39). However, the analysis of fusion between just two chromosome ends is limiting; increasing the scope of the assay to include more ends will improve the sensitivity and allow the detection of rare fusion events; which will be important in examining telomere fusion directly from human tissue in both normal and disease contexts. It will also allow the detection of a broader range of fusion structures and the identification of specific chromosome ends in the human genome that are subjected to fusion. We therefore chose to expand the scope of this assay by including PCR primers based within the complex subtelomeric sequences that are shared between multiple chromosome ends (40). Two subtelomeric sequence families were chosen for analysis; one family included the telomeres of 21q, 1q, 2q, 5q, 6q, 6p, 8p, 10q, 13q, 17q, 19p, 19q, 22q and the 2q13 interstitial telomeric locus representing some of the telomeres detected with the TelBam 11 sequence (41); the other family included the 16p, 1p, 9p, 12p, 15q and XqYq telomeres, as well as the 2q14 interstitial locus (42), representing telomeres detected with the TelBam3.4 sequence (35,36,41) (Figure 1A). We refer to these telomere families as the 21q and 16p telomere groups, respectively.

A valuable aspect of these assays is the ability to characterize the DNA sequence of fusion events; this provides verification that the fusion events are genuine, and allows one to examine the underlying biology. However, fusion within the 21q or the 16p telomere family members is likely to result in the creation of palindromic sequences and it is not practical to sequence these events directly. Thus, for the initial development of the assay we used

PCR primers targeted to the 21q and 16p family in conjunction with the specific chromosome ends XpYp and 17p. To validate the assay, we used HEK293 cells which we had previously shown to exhibit fusion between the XpYp and 17p telomeres at a high frequency (2). HEK293 cells express telomerase but maintain telomere length distributions that extend to within the length range that we had previously detected fusion events (2). Combining the 17p, XpYp and 21q primers resulted in an increase (2.9×) in the number of fusions detected (Figure 1B); an increase in the number of fusion events was also observed when combining 17p, XpYp and 16p primers (data not shown). The combination of XpYp, 17p, 21q and 16p resulted in a further increase (4×) in the number of detectable fusion events (Figure 1B). Given the apparent success of these assays we then applied them to a clonal MRC5 fibroblast culture in which we had expressed HPVE6E7 oncoproteins (2). We have previously described that, in this culture, as the cells continued to divide beyond the point of senescence the telomeres continue to erode to a threshold length at which fusion events were detected between the XpYp and 17p telomeres (2). Crucially, there was no detectable change in telomere dynamics (erosion rates or frequencies of sporadic deletion) following HPVE6E7 expression (2). Using the 16p and 21q assays we observed a similar increase in the number of detectable fusion events with ongoing cell division through to the point of 'crisis', overall there was an increase in the number of detectable fusion events compared to that observed with the XpYp/17p fusion analysis alone (Figure 1B). The number of fusion events was so great in the MRC5 E6E7 cells undergoing 'crisis' that it appeared to interfere with the amplification creating some smearing on the gels, which was not apparent in samples with small numbers of fusions (Figure 1B).

The increase in the number of detectable fusion events with the modified assays indicated that we were detecting fusion between additional chromosome ends. In order to verify this and to examine the mutational spectrum, we undertook direct sequence analysis of single fusion events isolated from both HEK293 and MRC5 cells (Figure 2). The telomeres participating in each fusion event were identified by sequential Southern hybridization using telomere adjacent probes. Putative single fusion molecules were re-amplified with nested PCR primers and in order to identify the fusion points as well as the specific telomeres involved in each event, multiple sequencing reactions were undertaken for each fusion product. We sequenced a total of 298 fusion events; 125 events from HEK293 cells (of which  $n = 41$  and  $n = 84$  were from the 16p and 21q groups, respectively) and 173 events from MRC5 cells (of which  $n = 71$  and  $n = 102$  were from the 16p and 21q, groups, respectively). Fusions were detected between either 17p or XpYp and several telomeres within the 21q and 16p families. This demonstrated that our assays were capable of detecting fusion between the multiple chromosome ends targeted in the assay.





**Figure 3.** Histograms summarizing the data from the telomere fusion analysis in telomerase-positive epithelial HEK293 (open bars) and telomerase-negative MRC5 cells expressing HPV oncoproteins E6E7 from all three PD points sampled (solid bars). (A–D) The deletion size from the start of the telomere repeat arrays for 16p group, 21q group, XpYp and 17p, respectively. (E) Size of 100% sequence homology at the fusion point. (F) Number of contiguous TTAGGG repeats at the fusion point. Means  $\pm$  SD for each data set are indicated.

frequency of fusion events appeared to remain constant per unit length. These profiles indicate that sub-telomeric deletion prior to the fusion may be more extensive than that detected here, extending up to and beyond the limit of our assays.

In addition to the characteristic deletion events that accompany telomere fusion, the majority of fusion events (60–74% in HEK293 and MRC5 respectively) exhibited short patches (1–12 nt, overall mean 1.7 nt) of 100% sequence homology (Figure 3E). Compared to the A:T/G:C content of the telomere-adjacent sequences studied here (48% A:T, 52% G:C) there was a significant bias towards G:C base pairs within the regions of microhomology at the fusion points (39% A:T, 61% G:C,  $P = 0.002$  chi-square).

#### Telomere length and fusion

The frequency of fusion increased in the MRC5 E6E7 cells with ongoing cell division as the cells approached crisis (Figure 1B). Interestingly, these cells displayed fusion between either XpYp or 17p and just two of the nine telomeres within the 21q group (10q and 21q); this was in contrast to the HEK293 cells where fusion was detected

involving seven different telomeres in the 21q group. This indicated that in MRC5 cells a specific subset of telomeres may have eroded to a length at which they became subjected to fusion, whereas the other chromosome ends within the 21q family had not.

The TTAGGG telomere repeat content at the fusion junctions was limited, with 38% to 60% of fusions in the HEK293 and MRC5 cells, respectively containing no telomere repeats (Figure 3F). Of the fusions that did contain TTAGGG repeats immediately adjacent to the fusion point, the mean length was  $5.8 \pm 0.7$  (SE) repeats. Single examples of longer segments of contiguous TTAGGG repeats adjacent to the fusion point were also observed with the largest block of 43 repeats observed in MRC5 cells; further sampling may yield longer telomeres involved in fusion (Figure 3F). Just one fusion event of the total 298 sequenced revealed telomere repeats on each side of the fusion point, in this case 6.5 repeats from 17p and 3.5 repeats from 10q (Figure 2B). This was consistent with our previous observations, where the paucity of fusion events containing telomere repeats on either side of the fusion point was not accounted for by the resulting inverted repeats being refractory to PCR (2).





contained blocks of repeat variants, without an obvious origin, immediately adjacent to the fusion point (Figure 4).

### Complex fusion events

We observed fusion between both the 17p and XpYp telomeres and the interstitial ancestral telomere–telomere fusion at 2q14, this locus is approximately 130 Mb from the 2q telomere (Figure 2C) (42). It could not be determined whether this represented fusion following a large-scale subtelomeric deletion process initiated from the 2q telomere, or fusion directly with a *de novo* DNA double-strand break that occurred near this locus; however, it was clear that dysfunctional telomeres are capable of fusion to non-telomeric loci. Indeed, we detected fusion events (34/298, 11%) that contained additional genomic sequences inserted between the fused telomeres (Figure 2D). The genomic locus of four insertions could be identified; one was derived from 8q24.3, one from 7p21.1 and two from Xp22.1. Interestingly, these loci, as well as 2q14, are all close to fragile chromosomal sites (45,46). Two of the insertion events contained sequences from the originating telomere inserted in the reverse orientation. In MRC5 cells where the XpYp telomeric alleles could be identified by numerous SNPs in the telomere adjacent DNA (2,37), it was clear that these inverted insertions were derived from the same allele involved in the fusion event, and were therefore, intra-allelic (Figure 2E). The remaining 28 insertion events were too small to identify the originating chromosomal locus (Figure 2F).

We also detected fusion events between the XpYp and XqYq telomeres in 23 out of the 112 fusion events sequenced involving the 16p group of telomeres (21%, Figures 2A and 2F); such events may result in the formation of ring chromosomes.

## DISCUSSION


Here, we have described a comprehensive analysis of telomere fusion between multiple chromosome ends in human cells. These assays can detect sister chromatid-type fusion when there has been a deletion of at least one of the telomere repeat arrays creating an imperfect inverted repeat, they can also detect fusion between heterologous chromosomes containing substantial arrays of head-to-head telomere repeats that arise following TRF2 depletion (2). They cannot however, detect the presence of sister chromatid-type fusions that create perfect inverted repeat sequences (2). Interestingly, studies using telomere-adjacent I-SceI induced breaks, show that the majority (90%) of selected clones had undergone chromosomal ‘healing’ by the addition of new telomere (47). Of those clones that had not undergone chromosomal healing, inverted repeats close to the site of the original break was the most common event; this is consistent with sister chromatid fusion (48). The majority of events that are detected with our assays involved heterologous chromosomes, with 5% of events that were consistent with sister chromatid fusion (2). The difference

between these two datasets may be related to the fact that our data is examining telomere fusion in the context of widespread telomeric dysfunction across multiple chromosomes, compared to the selection of events involving breakage at a single chromosome end in the context of otherwise functional telomeres at the other chromosome ends.

It is clear from our previous work (2), as well as that from other labs (48,49), together with the large data set described here, that the fusion of short dysfunctional telomeres is accompanied by telomeric and sub-telomeric deletion. This profile is also consistent with studies using I-SceI induced double-strand breaks where larger deletions were observed at telomeric loci (49). The size profile of these deletion events indicates that deletion is likely to extend beyond the proximal limit of our assays, which at the 16p group is 6.1 kb. Whilst the mechanism of deletion has not been characterized, studies using conditional *cdc13* mutants in *Saccharomyces cerevisiae* show that the *exol* dependent single-stranded DNA can extend for at least 8 kb from the start of the telomere (50). Furthermore, breakpoint frequency within the terminal chromosomal bands observed in pancreatic carcinoma and osteosarcoma has been shown to negatively correlate with telomere length at specific chromosome ends (15). This data was determined from karyotype analysis and therefore the distance of the breakpoints within the terminal bands may be several mega base pairs from the chromosomal terminus. Thus, we consider that the subtelomeric deletion that follows the formation of short dysfunctional telomeres could be extensive, and may include terminal coding regions. Several genes have been identified close to the telomere, for example members of the Wiskott–Aldrich Syndrome Protein and Scar homolog (WASH) gene family lie within 5 kb from the start of the telomere repeat array (51). Therefore, irrespective of whether they undergo fusion, or healing by *de novo* telomere formation, the extensive deletion events that occur at short dysfunctional telomeres are likely to create a significant mutational burden. Indeed it is clear that terminal chromosomal deletions have been implicated in numerous clinical genetic conditions (52,53).

The extensive deletion that accompanies telomere fusion together with microhomology at the fusion junction may be indicative of the DNA repair processes that mediate fusion between short dysfunctional telomeres. The limited homology at the fusion junction, together with the extensive deletion, appear inconsistent with single-stranded annealing or NHEJ as being the predominant mechanisms underlying fusion; both these mechanisms have, in different contexts, been described to mediate telomere fusion (23,54). An alternative NHEJ pathway has been described in mammalian cells (55,56) that is DNA-PK independent. This pathway is considered to be error-prone resulting in extensive deletion (55,57) and is facilitated by microhomology at the fusion point with a bias toward G:C base pairs (58). The profile that accompanies DNA-PK-independent NHEJ is reminiscent of the extensive deletion and microhomology with a G:C bias described here following the fusion of short dysfunctional telomeres. This alternative NHEJ pathway





**Figure 5.** Illustrating a model, for the sequence of events, that may account for intra-allelic inverted insertion that accompanies a subset of telomere fusion events. This model is using the fusion sequence depicted in Figure 2F as an example, the deletion points are indicated as distances from the start of the telomere repeat array. (A–B) Short telomeres become de-protected and are subjected to nucleolytic resection, yielding a 3'-overhang within the telomere-adjacent DNA. (C) The 3'-end of the overhang (–111) folds back upon itself and anneals adjacent to the –596 position, this is ligated and endonucleolytic cleavage creates a 5'-overhang structure which can be rendered double-stranded by strand extension (D). Further resection (E) to the –356 position creates a substrate (F) for annealing and ligation of the 1p sub-telomere at position –1260 (G). Endonucleolytic cleavage removes the unpaired 3'-overhang from XpYp (G), strand extension and ligation complete the fusion (H–I).

may account for double-strand break repair in the absence of functional classical NHEJ in some tumours (59), V(D)J recombination and IgH class switching in mouse models (60,61) and thus is physiologically relevant. This pathway is poorly characterized and the involvement, if any, of the key proteins required in this pathway such as PARP-1 and Ligase III (62–64), in telomere fusion, has yet to be established. It will be of interest to ascertain which pathway mediates the fusion between short dysfunctional telomeres.

We observed fusion events in which there was an insertion of additional telomere-adjacent DNA, which was derived from one of the two telomeres involved in the fusion event. Informative SNPs allowed us to establish

that the inserted DNA was derived from the same telomeric allele involved in the fusion event and it was therefore an intra-allelic event. Furthermore, in all the examples of this type of fusion, the DNA was inserted in the reverse orientation with respect to the telomere repeat array. These observations lead us to consider that the fusion event involved an intra-molecular rearrangement prior to the final fusion between the two chromosomes. We propose the following sequence of events as illustrated in Figure 5, as a speculative model to account for both the presence of multiple fusion points within the same single molecule and the reverse orientation of the insertion. In this model short telomeres lose their end protection function, possibly because of a lack of TRF1 and

TRF2 binding sites, the telomere is then subjected to extensive resection creating a region of single-stranded DNA (Figure 5A–B). The 3'-end of this single-stranded DNA folds back upon itself and anneals at points of microhomology that are sufficiently stable to facilitate ligation (Figure 5C). The intra-molecular loop is then processed by endonucleolytic cleavage to create a 5'-overhang with the inversion and one fusion junction in place (Figure 5D). The 5'-overhang is then rendered double-stranded by strand extension, and subjected to further 5'–3' resection to create a substrate for fusion (Figure 5E–F) with another telomere or double-stranded DNA break (Figure 5G–I). An alternative mechanism as elaborated previously (20,21,49) could involve an initial sister chromatid fusion. This creates an imperfect inverted repeat which forms a fragile site that breaks following anaphase bridging close to the site of the first fusion, this broken end now contains an inversion which then fuses to the second chromosome involved in the fusion event.

We observed numerous examples of fusion between XpYp and XqYq; such events have the potential to create circular chromosomes. These ring chromosomes can occur constitutively, resulting in variable clinical consequences which is not consistent with a loss of genetic material in the originating ring chromosome (65,66). Some examples of ring chromosomes, such as ring chromosome 19, indicate they have formed as a consequence of telomere fusion without any cytogenetically detectable terminal deletion (67). Thus, it has been postulated that 'ring syndromes' result from the subsequent mitotic instability of the ring chromosome (66). Ring chromosomes are also frequently detected in tumour cells, and have been shown to be highly unstable and undergo continuous rearrangements (68); resulting in potentially oncogenic amplification and deletion (69). Interestingly, some tumour types for example liposarcomas and parosteal osteosarcoma exhibit ring chromosomes in over 90% of tumours (70–72). Whereas other cancer types, including many types of carcinoma, the frequency of ring chromosomes is much less <10% of cases (72).

Extensive variation in the human population in the distribution patterns of telomere repeat variants that occur in the proximal 2–3 kb of telomere repeat arrays has been described (37,44). Differences in the TVR distributions of related telomeric alleles indicate a pattern of intra-allelic mutation, which is remarkably similar to that as described here in the TVR distributions obtained from single cells of the same cell strain. The patterns of mutation, including repeat expansion and contraction, and mutation within the telomere repeats themselves, are consistent with errors during replication such as stuttering of the replication fork. Consistent with this, telomere repeat arrays, as well as other repetitive loci, present a problem for the replication fork, and as such, require additional processing to facilitate progression (73–75).

Analysis of the TVR distributions also revealed the presence of two fusions with additional repeat variants immediately adjacent to the fusion point; these did not appear to be derived from the progenitor allele. We considered that this may be related to the process of fusion,

with the possibility of processing of a heteroduplex at the fusion point creating a scrambled repeat structure; however, this appeared unlikely as the general repeat structure was conserved and the DNA sequence of the participating chromosome did not contain the correct bases. Instead, we consider that these inserted repeats may represent an insertion of additional DNA derived from another telomere during the fusion event.

All the fusion events that involved non-telomeric loci, 2q14, 8q24.3, 7p21.1 and Xp22.1, were identified within the same cytogenetic location as previously documented fragile sites (45,46). In contrast to normal cells, fragile sites are involved in chromosomal rearrangements in tumour cells, these are typically deletions, but translocations involving fragile sites have also been identified (76–78). The fusion of short dysfunctional telomeres with fragile sites may thus provide one mechanism to generate large-scale genomic rearrangements in cancer cells.

Whatever the underlying mechanisms that generate the fusion structures described here, it is clear from this data, that short dysfunctional telomeres can be subjected to considerable processing prior to fusion, creating complex structures and substantial deletion.

## SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

## ACKNOWLEDGEMENTS

We thank Harold Riethman (Wistar institute) for providing telomere-adjacent sequence information. We also thank the staff at the sequencing facility of the Cardiff University Central Biotechnology Service.

## FUNDING

Cancer Research UK (grant no. C1799/A6932; C1799/A5603). Funding for open access charge: Cancer Research UK (grant no. C1799/A6932).

*Conflict of interest statement.* None declared.

## REFERENCES

- Maser, R.S., Wong, K.K., Sahin, E., Xia, H., Naylor, M., Hedberg, H.M., Artandi, S.E. and DePinho, R.A. (2007) DNA-dependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse. *Mol. Cell Biol.*, **27**, 2253–2265.
- Capper, R., Britt-Compton, B., Tankimanova, M., Rowson, J., Letsolo, B., Man, S., Haughton, M. and Baird, D.M. (2007) The nature of telomere fusion and a definition of the critical telomere length in human cells. *Genes Dev.*, **21**, 2495–2508.
- Counter, C.M., Ailion, A.A., LeFeuvre, C.E., Stewart, N.G., Greider, C.W., Harley, C.B. and Bacchetti, S. (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. *EMBO J.*, **11**, 1921–1929.
- van Steensel, B., Smogorzewska, A. and de Lange, T. (1998) TRF2 protects human telomeres from end-to-end fusions. *Cell*, **92**, 401–413.

5. Murnane, J.P. and Sabatier, L. (2004) Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. *Bioessays*, **26**, 1164–1174.
6. Artandi, S.E., Chang, S., Lee, S.L., Alson, S., Gottlieb, G.J., Chin, L. and DePinho, R.A. (2000) Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. *Nature*, **406**, 641–645.
7. Mitelman, F., Johansson, B., Mandahl, N. and Mertens, F. (1997) Clinical significance of cytogenetic findings in solid tumors. *Cancer Genet. Cytogenet.*, **95**, 1–8.
8. Shih, I.M., Zhou, W., Goodman, S.N., Lengauer, C., Kinzler, K.W. and Vogelstein, B. (2001) Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. *Cancer Res.*, **61**, 818–822.
9. Hastie, N.D., Dempster, M., Dunlop, M.G., Thompson, A.M., Green, D.K. and Allshire, R.C. (1990) Telomere reduction in human colorectal carcinoma and with ageing. *Nature*, **346**, 866–868.
10. Engelhardt, M., Drullinsky, P., Guillem, J. and Moore, M.A. (1997) Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. *Clin. Cancer Res.*, **3**, 1931–1941.
11. Nakamura, K., Furugori, E., Esaki, Y., Arai, T., Sawabe, M., Okayasu, I., Fujiwara, M., Kammori, M., Mafune, K., Kato, M. *et al.* (2000) Correlation of telomere lengths in normal and cancers tissue in the large bowel. *Cancer Lett.*, **158**, 179–184.
12. Rudolph, K.L., Millard, M., Bosenberg, M.W. and DePinho, R.A. (2001) Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. *Nat. Genet.*, **28**, 155–159.
13. Chin, K., de Solorzano, C.O., Knowles, D., Jones, A., Chou, W., Rodriguez, E.G., Kuo, W.L., Ljung, B.M., Chew, K., Myambo, K. *et al.* (2004) In situ analyses of genome instability in breast cancer. *Nat. Genet.*, **36**, 984–988.
14. Gordon, K.E., Ireland, H., Roberts, M., Steeghs, K., McCaul, J.A., MacDonald, D.G. and Parkinson, E.K. (2003) High levels of telomere dysfunction bestow a selective disadvantage during the progression of human oral squamous cell carcinoma. *Cancer Res.*, **63**, 458–467.
15. Gisselsson, D., Jonson, T., Petersen, A., Strombeck, B., Dal Cin, P., Hoglund, M., Mitelman, F., Mertens, F. and Mandahl, N. (2001) Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. *Proc. Natl Acad. Sci. USA*, **98**, 12683–12688.
16. Gisselsson, D., Jonson, T., Yu, C., Martins, C., Mandahl, N., Wiegant, J., Jin, Y., Mertens, F. and Jin, C. (2002) Centrosomal abnormalities, multipolar mitoses, and chromosomal instability in head and neck tumours with dysfunctional telomeres. *Br. J. Cancer*, **87**, 202–207.
17. Gisselsson, D., Gorunova, L., Hoglund, M., Mandahl, N. and Elfving, P. (2004) Telomere shortening and mitotic dysfunction generate cytogenetic heterogeneity in a subgroup of renal cell carcinomas. *Br. J. Cancer*, **91**, 327–332.
18. Rudolph, K.L., Chang, S., Lee, H.W., Blasco, M., Gottlieb, G.J., Greider, C. and DePinho, R.A. (1999) Longevity, stress response, and cancer in aging telomerase-deficient mice. *Cell*, **96**, 701–712.
19. O'Hagan, R.C., Chang, S., Maser, R.S., Mohan, R., Artandi, S.E., Chin, L. and DePinho, R.A. (2002) Telomere dysfunction provokes regional amplification and deletion in cancer genomes. *Cancer Cell*, **2**, 149–155.
20. Lo, A.W., Sabatier, L., Fouladi, B., Pottier, G., Ricoul, M. and Murnane, J.P. (2002) DNA amplification by breakage/fusion/bridge cycles initiated by spontaneous telomere loss in a human cancer cell line. *Neoplasia*, **4**, 531–538.
21. Murnane, J.P. (2006) Telomeres and chromosome instability. *DNA Repair*, **5**, 1082–1092.
22. Celli, G.B., Denchi, E.L. and de Lange, T. (2006) Ku70 stimulates fusion of dysfunctional telomeres yet protects chromosome ends from homologous recombination. *Nat. Cell Biol.*, **8**, 885–890.
23. Smogorzewska, A., Karlseder, J., Holtgreve-Grez, H., Jauch, A. and de Lange, T. (2002) DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2. *Curr. Biol.*, **12**, 1635–1644.
24. Baumann, P. and Cech, T.R. (2000) Protection of telomeres by the Ku protein in fission yeast. *Mol. Biol. Cell*, **11**, 3265–3275.
25. Heacock, M.L., Idol, R.A., Friesner, J.D., Britt, A.B. and Shippen, D.E. (2007) Telomere dynamics and fusion of critically shortened telomeres in plants lacking DNA ligase IV. *Nucleic Acids Res.*, **35**, 6490–6500.
26. Heacock, M., Spangler, E., Riha, K., Puizina, J. and Shippen, D.E. (2004) Molecular analysis of telomere fusions in Arabidopsis: multiple pathways for chromosome end-joining. *EMBO J.*, **23**, 2304–2313.
27. Boulton, S.J. and Jackson, S.P. (1996) *Saccharomyces cerevisiae* Ku70 potentiates illegitimate DNA double-strand break repair and serves as a barrier to error-prone DNA repair pathways. *EMBO J.*, **15**, 5093–5103.
28. Gottlich, B., Reichenberger, S., Feldmann, E. and Pfeiffer, P. (1998) Rejoining of DNA double-strand breaks in vitro by single-strand annealing. *Eur. J. Biochem.*, **258**, 387–395.
29. Ma, J.L., Kim, E.M., Haber, J.E. and Lee, S.E. (2003) Yeast Mre11 and Rad1 proteins define a Ku-independent mechanism to repair double-strand breaks lacking overlapping end sequences. *Mol. Cell Biol.*, **23**, 8820–8828.
30. Yu, X. and Gabriel, A. (2003) Ku-dependent and Ku-independent end-joining pathways lead to chromosomal rearrangements during double-strand break repair in *Saccharomyces cerevisiae*. *Genetics*, **163**, 843–856.
31. Graham, F.L., Smiley, J., Russell, W.C. and Nairn, R. (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *J. Gen. Virol.*, **36**, 59–74.
32. Wright, W.E., Pereira-Smith, O.M. and Shay, J.W. (1989) Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. *Mol. Cell Biol.*, **9**, 3088–3092.
33. Sambrook, J., Fritsh, E.F. and Maniatis, T. (1989) *Molecular Cloning: a Laboratory Manual*, 2nd edn. Cold spring harbour laboratory press, New York.
34. Brown, W.R., Dobson, M.J. and MacKinnon, P. (1990) Telomere cloning and mammalian chromosome analysis. *J. Cell Sci.*, **95** (Pt 4), 521–526.
35. Riethman, H., Ambrosini, A., Castaneda, C., Finklestein, J., Hu, X.L., Mudunuri, U., Paul, S. and Wei, J. (2004) Mapping and initial analysis of human subtelomeric sequence assemblies. *Genome Res.*, **14**, 18–28.
36. Riethman, H., Ambrosini, A. and Paul, S. (2005) Human subtelomere structure and variation. *Chromosome Res.*, **13**, 505–515.
37. Baird, D.M., Jeffreys, A.J. and Royle, N.J. (1995) Mechanisms underlying telomere repeat turnover, revealed by hypervariable variant repeat distribution patterns in the human Xp/Yp telomere. *EMBO J.*, **14**, 5433–5443.
38. Baird, D.M., Rowson, J., Wynford-Thomas, D. and Kipling, D. (2003) Extensive allelic variation and ultrashort telomeres in senescent human cells. *Nat. Genet.*, **33**, 203–207.
39. Britt-Compton, B., Rowson, J., Locke, M., Mackenzie, I., Kipling, D. and Baird, D.M. (2006) Structural stability and chromosome-specific telomere length is governed by cis-acting determinants in humans. *Hum. Mol. Genet.*, **15**, 725–733.
40. Ambrosini, A., Paul, S., Hu, S. and Riethman, H. (2007) Human subtelomeric duplicon structure and organization. *Genome Biol.*, **8**, R151.
41. Brown, W.R., MacKinnon, P.J., Villasante, A., Spurr, N., Buckle, V.J. and Dobson, M.J. (1990) Structure and polymorphism of human telomere-associated DNA. *Cell*, **63**, 119–132.
42. Ijdo, J.W., Baldini, A., Ward, D.C., Reeders, S.T. and Wells, R.A. (1991) Origin of human chromosome 2: an ancestral telomere-telomere fusion. *Proc. Natl Acad. Sci. USA*, **88**, 9051–9055.
43. Allshire, R.C., Dempster, M. and Hastie, N.D. (1989) Human telomeres contain at least three types of G-rich repeat distributed non-randomly. *Nucleic Acids Res.*, **17**, 4611–4627.
44. Baird, D.M., Coleman, J., Rosser, Z.H. and Royle, N.J. (2000) High levels of sequence polymorphism and linkage disequilibrium at the telomere of 12q: implications for telomere biology and human evolution. *Am. J. Hum. Genet.*, **66**, 235–250.
45. Debacker, K. and Kooy, R.F. (2007) Fragile sites and human disease. *Hum. Mol. Genet.*, **16**(Spec No. 2), R150–R158.

46. Chen, C.H., Shih, H.H., Wang-Wuu, S., Tai, J.J. and Wu, K.D. (1998) Chromosomal fragile site expression in lymphocytes from patients with schizophrenia. *Hum. Genet.*, **103**, 702–706.
47. Sprung, C.N., Reynolds, G.E., Jasin, M. and Murnane, J.P. (1999) Chromosome healing in mouse embryonic stem cells. *Proc. Natl Acad. Sci. USA*, **96**, 6781–6786.
48. Lo, A.W., Sprung, C.N., Fouladi, B., Pedram, M., Sabatier, L., Ricoul, M., Reynolds, G.E. and Murnane, J.P. (2002) Chromosome instability as a result of double-strand breaks near telomeres in mouse embryonic stem cells. *Mol. Cell Biol.*, **22**, 4836–4850.
49. Zschenker, O., Kulkarni, A., Miller, D., Reynolds, G.E., Granger-Locatelli, M., Pottier, G., Sabatier, L. and Murnane, J.P. (2009) Increased sensitivity of subtelomeric regions to DNA double-strand breaks in a human cancer cell line. *DNA Repair*, **8**, 886–900.
50. Maringe, L. and Lydall, D. (2002) EXO1-dependent single-stranded DNA at telomeres activates subsets of DNA damage and spindle checkpoint pathways in budding yeast yku70Delta mutants. *Genes Dev.*, **16**, 1919–1933.
51. Riethman, H. (2008) Human telomere structure and biology. *Annu. Rev. Genomics Hum. Genet.*, **9**, 1–19.
52. Flint, J. and Knight, S. (2003) The use of telomere probes to investigate submicroscopic rearrangements associated with mental retardation. *Curr. Opin. Genet. Dev.*, **13**, 310–316.
53. Pinson, L., Perrin, A., Plouzenec, C., Parent, P., Metz, C., Collet, M., Le Bris, M.J., Douet-Guilbert, N., Morel, F. and De Braekeleer, M. (2005) Detection of an unexpected subtelomeric 15q26.2 → qter deletion in a little girl: clinical and cytogenetic studies. *Am. J. Med. Genet. A*, **138A**, 160–165.
54. Wang, X. and Baumann, P. (2008) Chromosome fusions following telomere loss are mediated by single-strand annealing. *Mol. Cell*, **31**, 463–473.
55. Feldmann, E., Schmiemann, V., Goedecke, W., Reichenberger, S. and Pfeiffer, P. (2000) DNA double-strand break repair in cell-free extracts from Ku80-deficient cells: implications for Ku serving as an alignment factor in non-homologous DNA end joining. *Nucleic Acids Res.*, **28**, 2585–2596.
56. Wang, H., Perrault, A.R., Takeda, Y., Qin, W. and Iliakis, G. (2003) Biochemical evidence for Ku-independent backup pathways of NHEJ. *Nucleic Acids Res.*, **31**, 5377–5388.
57. Guirouilh-Barbat, J., Huck, S., Bertrand, P., Pirzio, L., Desmaze, C., Sabatier, L. and Lopez, B.S. (2004) Impact of the KU80 pathway on NHEJ-induced genome rearrangements in mammalian cells. *Mol. Cell*, **14**, 611–623.
58. Audebert, M., Salles, B. and Calsou, P. (2008) Effect of double-strand break DNA sequence on the PARP-1 NHEJ pathway. *Biochem. Biophys. Res. Commun.*, **369**, 982–988.
59. Bentley, J., Diggle, C.P., Harnden, P., Knowles, M.A. and Kiltie, A.E. (2004) DNA double strand break repair in human bladder cancer is error prone and involves microhomology-associated end-joining. *Nucleic Acids Res.*, **32**, 5249–5259.
60. Corneo, B., Wendland, R.L., Deriano, L., Cui, X., Klein, I.A., Wong, S.Y., Arnal, S., Holub, A.J., Weller, G.R., Pancake, B.A. et al. (2007) Rag mutations reveal robust alternative end joining. *Nature*, **449**, 483–486.
61. Yan, C.T., Boboila, C., Souza, E.K., Franco, S., Hickernell, T.R., Murphy, M., Gumaste, S., Geyer, M., Zarrin, A.A., Manis, J.P. et al. (2007) IgH class switching and translocations use a robust non-classical end-joining pathway. *Nature*, **449**, 478–482.
62. Audebert, M., Salles, B. and Calsou, P. (2004) Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. *J. Biol. Chem.*, **279**, 55117–55126.
63. Audebert, M., Salles, B., Weinfeld, M. and Calsou, P. (2006) Involvement of polynucleotide kinase in a poly(ADP-ribose) polymerase-1-dependent DNA double-strand breaks rejoining pathway. *J. Mol. Biol.*, **356**, 257–265.
64. Wang, M., Wu, W., Rosidi, B., Zhang, L., Wang, H. and Iliakis, G. (2006) PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. *Nucleic Acids Res.*, **34**, 6170–6182.
65. Luciani, J.J., de Mas, P., Depetris, D., Mignon-Ravix, C., Bottani, A., Prieur, M., Jonveaux, P., Philippe, A., Bourrouillou, G., de Martinville, B. et al. (2003) Telomeric 22q13 deletions resulting from rings, simple deletions, and translocations: cytogenetic, molecular, and clinical analyses of 32 new observations. *J. Med. Genet.*, **40**, 690–696.
66. Kosztolanyi, G. (1987) Does “ring syndrome” exist? An analysis of 207 case reports on patients with a ring autosome. *Hum. Genet.*, **75**, 174–179.
67. Sawyer, J.R., Rowe, R.A., Hased, S.J. and Cunniff, C. (1993) High-resolution cytogenetic characterization of telomeric associations in ring chromosome 19. *Hum. Genet.*, **91**, 42–44.
68. Gisselsson, D., Hoglund, M., Mertens, F., Mitelman, F. and Mandahl, N. (1998) Chromosomal organization of amplified chromosome 12 sequences in mesenchymal tumors detected by fluorescence in situ hybridization. *Genes Chromosomes Cancer*, **23**, 203–212.
69. Gisselsson, D., Hoglund, M., Mertens, F., Johansson, B., Dal Cin, P., Van den Berghe, H., Earnshaw, W.C., Mitelman, F. and Mandahl, N. (1999) The structure and dynamics of ring chromosomes in human neoplastic and non-neoplastic cells. *Hum. Genet.*, **104**, 315–325.
70. Sinovic, J.F., Bridge, J.A. and Neff, J.R. (1992) Ring chromosome in parosteal osteosarcoma. Clinical and diagnostic significance. *Cancer Genet. Cytogenet.*, **62**, 50–52.
71. Heim, S., Mandahl, N., Kristoffersson, U., Mitelman, F., Rooser, B., Rydholm, A. and Willen, H. (1987) Marker ring chromosome—a new cytogenetic abnormality characterizing lipogenic tumors? *Cancer Genet. Cytogenet.*, **24**, 319–326.
72. Gisselsson, D. (2002) Ring chromosomes: vicious circles at the end and beginning of life. *Atlas Genet. Cytogenet. Oncol. Haematol.*, **6**, 370–380.
73. Miller, K.M., Rog, O. and Cooper, J.P. (2006) Semi-conservative DNA replication through telomeres requires Taz1. *Nature*, **440**, 824–828.
74. Ohki, R. and Ishikawa, F. (2004) Telomere-bound TRF1 and TRF2 stall the replication fork at telomeric repeats. *Nucleic Acids Res.*, **32**, 1627–1637.
75. Baird, D.M. (2008) Mechanisms of telomeric instability. *Cytogenet. Genome Res.*, **122**, 308–314.
76. Mimori, K., Druck, T., Inoue, H., Alder, H., Berk, L., Mori, M., Huebner, K. and Croce, C.M. (1999) Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. *Proc. Natl Acad. Sci. USA*, **96**, 7456–7461.
77. Huebner, K. and Croce, C.M. (2001) FRA3B and other common fragile sites: the weakest links. *Nat. Rev. Cancer*, **1**, 214–221.
78. Michael, D., Beer, D.G., Wilke, C.W., Miller, D.E. and Glover, T.W. (1997) Frequent deletions of FHIT and FRA3B in Barrett’s metaplasia and esophageal adenocarcinomas. *Oncogene*, **15**, 1653–1659.